New Phase 3 trials registered, week of October 5, 2026: 11 industry trials

Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.

The trials

Shanghai Henlius Biotech registers Phase II/III study of HLX37 in first-line NSCLC. Sponsor: Shanghai Henlius Biotech. Condition: NSCLC (Advanced Non-small Cell Lung Cancer). Interventions: Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion), Paclitaxel or Nab-Paclitaxel, Pemetrexed (1), Investigational drug: HLX37 dose2, IV, Q3W. Phase: Phase 2/Phase 3. Planned enrollment: 1,438. Planned primary completion: December 2030. First posted October 8, 2026. Record: NCT07865910.
Amgen registers Phase 3 trial of maridebart cafraglutide versus semaglutide in type 2 diabetes. Sponsor: Amgen. Condition: Diabetes Mellitus, Type 2. Interventions: Maridebart cafraglutide, Semaglutide. Phase: Phase 3. Planned enrollment: 1,300. Planned primary completion: September 2028. First posted October 8, 2026. Record: NCT07866066 (MARITIME-T2D-3).
Sagimet registers Phase 3 trial of denifanstat in moderate to severe acne vulgaris. Sponsor: Sagimet Biosciences Inc. Condition: Acne Vulgaris. Intervention: Denifanstat. Phase: Phase 3. Planned enrollment: 800. Planned primary completion: August 2027. First posted October 7, 2026. Record: NCT07863193.
Chiesi registers Phase 3 trial of CHF5993 vs Seretide in adolescent asthma. Sponsor: Chiesi Farmaceutici S.p.A. Condition: Asthma. Interventions: CHF5993 100/6/12.5 μg pMDI HFA-152a, Seretide Evohaler. Phase: Phase 3. Planned enrollment: 700. Planned primary completion: June 2030. First posted October 5, 2026. Record: NCT07858123 (TRIADES).
Genmab registers Phase 3 trial of Rina-S in ovarian cancer. Sponsor: Genmab. Condition: Ovarian Cancer. Interventions: Rina-S, Bevacizumab. Phase: Phase 3. Planned enrollment: 602. Planned primary completion: March 2030. First posted October 5, 2026. Record: NCT07859215 (RAINFOL™-10).
Viking Therapeutics registers Phase 3 trial of VK2735 for weight management in type 2 diabetes. Sponsor: Viking Therapeutics, Inc. Condition: Weight Loss. Intervention: VK2735 Oral. Phase: Phase 3. Planned enrollment: 560. Planned primary completion: October 2028. First posted October 9, 2026. Record: NCT07868939.
Viking Therapeutics registers Phase 3 trial of VK2735 for weight management. Sponsor: Viking Therapeutics, Inc. Condition: Weight Loss. Intervention: VK2735. Phase: Phase 3. Planned enrollment: 560. Planned primary completion: July 2028. First posted October 9, 2026. Record: NCT07868835.
FrieslandCampina registers Phase 3 trial of infant formula with bio-active ingredients. Sponsor: FrieslandCampina. Condition: Infant ALL. Interventions: Infant Formula, Breastfeeding. Phase: Phase 3. Planned enrollment: 387. Planned primary completion: December 2028. First posted October 9, 2026. Record: NCT07867509.
GL Pharm Tech Corporation registers Phase 3 trial of W2505 for erectile dysfunction. Sponsor: GL Pharm Tech Corporation. Condition: Erectile Dysfunctions. Interventions: W2505, W2505-P1, W2505-R, W2505-P2. Phase: Phase 3. Planned enrollment: 228. Planned primary completion: July 2027. First posted October 5, 2026. Record: NCT07859202.
Pharmazz, Inc. registers Phase 3 study of sovateltide for acute traumatic brain injury. Sponsor: Pharmazz, Inc. Condition: Traumatic Brain Injury. Intervention: Sovateltide. Phase: Phase 3. Planned enrollment: 214. Planned primary completion: February 2028. First posted October 6, 2026. Record: NCT07861126 (RESTORE-TBI).
GlaxoSmithKline registers Phase 3 linerixibat safety eXtension study in Japan. Sponsor: GlaxoSmithKline. Condition: Pruritus. Intervention: Linerixibat. Phase: Phase 3. Planned enrollment: 40. Planned primary completion: October 2028. First posted October 6, 2026. Record: NCT07860710.

By the numbers

Trials: 11, from 10 lead sponsors.
Planned enrollment: 6,829 in all across 11 trials; median 560 per trial.
Largest: Shanghai Henlius Biotech's NCT07865910 trial, 1,438. Smallest: GlaxoSmithKline's Linerixibat trial, 40.
Sponsors with more than one trial: Viking Therapeutics, Inc. (2).
Phases as registered: 10 Phase 3, 1 Phase 2/Phase 3.
Planned primary completion: from July 2027 to December 2030.

How this page is made

Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Planned figures are the sponsor's estimates at registration.